News
INTS
5.46
-0.73%
-0.04
Weekly Report: what happened at INTS last week (0406-0410)?
Weekly Report · 20h ago
Weekly Report: what happened at INTS last week (0330-0403)?
Weekly Report · 04/06 09:02
INTENSITY THERAPEUTICS INC <INTS.O>: BENCHMARK ADJUSTS TARGET PRICE TO $12 FROM $1.50 TO REFLECT REVERSE STOCK SPLIT
Reuters · 03/31 11:15
U.S. RESEARCH ROUNDUP-Dutch Bros, Phreesia, Starbucks
Reuters · 03/31 07:39
Intensity Therapeutics upgraded to Buy from Hold at Freedom Broker
TipRanks · 03/30 20:00
Analysts Offer Insights on Healthcare Companies: Intensity Therapeutics, Inc. (INTS), IQVIA Holdings (IQV) and Xenon (XENE)
TipRanks · 03/30 11:30
Weekly Report: what happened at INTS last week (0323-0327)?
Weekly Report · 03/30 09:02
U.S. Tariff and Trade Policy Risks Threaten Intensity Therapeutics’ Supply Chain, Costs, and Stock Valuation
TipRanks · 03/29 06:01
Intensity Therapeutics GAAP EPS of -$8.56 misses by $0.69
Seeking Alpha · 03/27 20:33
Intensity Therapeutics Q4 EPS $(1.31) Misses $(0.04) Estimate
Benzinga · 03/27 20:18
INTENSITY THERAPEUTICS REPORTS 2025 YEAR END FINANCIAL RESULTS AND HIGHLIGHTS, AND PROVIDES CORPORATE UPDATE
Reuters · 03/27 20:12
Intensity Therapeutics FY2025 net loss narrows 28.66% to $(11.6) million; operating expenses drop 27.81% to $12.0 million
Reuters · 03/27 20:02
Intensity Therapeutics issued new patent in the US
TipRanks · 03/24 12:12
Intensity Therapeutics Issued New U.S. Patent Entitled 'A Method of Treating Cancer'
Benzinga · 03/24 12:09
Intensity Therapeutics wins US patent 12,496,345 for cancer treatment method
Reuters · 03/24 12:04
Intensity Therapeutics Expands ATM Equity Offering Capacity
TipRanks · 03/23 20:43
Intensity Therapeutics Expands ATM Offering Capacity To $60M; May Issue Up To $60M Of Common Stock Under Offering Agreement
Benzinga · 03/23 20:03
INTENSITY THERAPEUTICS INC FILES FOR COMMON STOCK OFFERING OF UP TO $60 MLN - SEC FILING
Reuters · 03/23 20:02
INTENSITY THERAPEUTICS INC - EXPANDED ATM FACILITY INTENDED TO ENHANCE FINANCIAL FLEXIBILITY - SEC FILING
Reuters · 03/23 20:02
Weekly Report: what happened at INTS last week (0316-0320)?
Weekly Report · 03/23 09:02
More
Webull provides a variety of real-time INTS stock news. You can receive the latest news about INTENSITY THERAPEUTICS INC through multiple platforms. This information may help you make smarter investment decisions.
About INTS
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.